PrimeC New Data to Be Presented at AD/PD™ 2026 Conference NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD 2026 in Copenhagen on March 19, 2026. The presentation reviews Phase 2b PARADIGM findings and biomarker analyses that informed the design of the planned global Phase 3 PARAGON trial.PARADIGM data were recently published in JAMA Neurology, and NeuroSense says it is actively engaging regulators as PARAGON — a multinational, randomized, double-blind, placebo-controlled study — is advanced to further evaluate PrimeC's safety and efficacy.

#NRSN #NRSNW PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

www.stocktitan.net/news/NRSN/prime-c-new-da...

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity The Journal of the American Medical Association publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2 b trial in ALS, including slower functional decline, reduced risk of ALS-related complications, and modulation of disease-relevant biomarkers. CAMBRIDGE, Mass., March 16, 2026/ PRNewswire/-- NeuroSense...

#NRSN #NRSNW JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

www.stocktitan.net/news/NRSN/jama-neurology...

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference NeuroSense (NASDAQ: NRSN) will present long-term survival data from the Phase 2b PARADIGM trial of PrimeC at the MDA Clinical & Scientific Conference on March 9, 2026. The analysis showed a 65% reduction in risk of death (HR 0.35; p=0.0037) and a >14-month median survival benefit (36.3 vs. 21.4 months; log-rank p=0.0218).The randomized, double-blind, placebo-controlled study enrolled 68 participants (2:1 randomization) with a six-month double-blind period followed by an open-label extension; safety was described as favorable.

#NRSN #NRSNW PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

www.stocktitan.net/news/NRSN/prime-c-long-t...

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.

#NRSN #NRSNW World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

www.stocktitan.net/news/NRSN/world-renowned...

#NRSN #NRSNW NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

www.stocktitan.net/news/NRSN/neuro-sense-to...